Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis

Satoru Taguchi(Iwate Medical University), Haruki Kume(The University of Tokyo), Yukari Uemura(University of Tokyo Hospital), Daisuke Yamada(International Research Center for Japanese Studies), Jun Kamei(The University of Tokyo), Keigo Sato(Meiji University), Mariko Tabata(The University of Tokyo), Satoru Takahashi(Nihon University), Tappei Takada(University of Tokyo Hospital), Michio Noda(Teikyo University), Katsuhiko Nara(University of Tokyo Hospital), Hiroaki Nishimatsu(Memorial Hospital of South Bend), Yutaka Enomoto(Mitsui Memorial Hospital), Kazuma Sugimoto(National Center for Global Health and Medicine), Tomoyuki Kaneko(Teikyo University), Jimpei Miyakawa(Kyorin University), Kenjiro Kishitani(The University of Tokyo), Daisuke Obinata(Nihon University), Takehiro Tanaka(Okayama University), Hiroshi Fukuhara(Kyorin University), Kenya Yamaguchi(Nihon University), Yusuke Sato(Akita University), Yuta Yamada(Yamagata University), Yukio Yamada(Musashino Red Cross Hospital), Hideyo Miyazaki(National Center for Global Health and Medicine), Yoshiyuki Akiyama(Tokyo Medical and Dental University), H Hoshina(Jichi Medical University), Aya Niimi(The University of Tokyo), Tohru Nakagawa(Sapporo Kosei General Hospital), Tetsuya Fujimura(Jichi Medical University), Yu Nakamura(Kyorin University), Yoshitsune Furuya, Sayuri Takahashi(Tokyo Medical University), Y. Ambe(The University of Tokyo), Yume Adachi(Musashino Red Cross Hospital), Shigenori Kakutani(The University of Tokyo), Yujiro Sato(The University of Tokyo), Taketo Kawai(National Center for Global Health and Medicine)
International Journal of Urology
November 22, 2024
Cited by 4


Related Papers